BrainsWay Ltd. carries a market capitalization of 675.08M, placing it among publicly traded companies globally. Its enterprise value stands at 405.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 675.08M |
| Enterprise Value | 405.47M |
BrainsWay Ltd. currently has 40.03M shares outstanding.
| Shares Outstanding | 40.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
BrainsWay Ltd. trades at a trailing price-to-earnings ratio of 52.01. The price-to-sales ratio is 8.16, and the price-to-book ratio stands at -5.21.
| PE Ratio | 52.01 |
| PS Ratio | 8.16 |
| PB Ratio | -5.21 |
| P/TBV Ratio | 6.05 |
| P/FCF Ratio | 28.03 |
| P/OCF Ratio | 32.33 |
On an enterprise value basis, BrainsWay Ltd. trades at an EV/EBITDA multiple of 55.08 and an EV/FCF ratio of 21.33. The EV/Sales ratio of 7.21 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 70.49 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.21 |
| EV / EBITDA | 55.08 |
| EV / EBIT | 70.49 |
| EV / FCF | 21.33 |
BrainsWay Ltd. maintains a current ratio of 3.34, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.85, indicating elevated leverage, while an interest coverage ratio of 3.50 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.34 |
| Quick Ratio | 2.86 |
| Debt / Equity | 8.85 |
| Debt / EBITDA | 0.91 |
| Interest Coverage | 3.50 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 8.12 |
| Return on Invested Capital (ROIC) | 7.54 |
| Return on Capital Employed (ROCE) | -12.64 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.34 |
Over the trailing twelve months, BrainsWay Ltd. has paid 40,000.00 in income taxes, reflecting an effective tax rate of 0.45.
| Income Tax | 40,000.00 |
| Effective Tax Rate | 0.45 |
BrainsWay Ltd.'s stock has gained approximately 395.29412% over the past 52 weeks. The 50-day moving average sits at 14.50, while the 200-day moving average is 9.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | 395.29412% |
| 50-Day Moving Average | 14.50 |
| 200-Day Moving Average | 9.89 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, BrainsWay Ltd. generated 56.22M in revenue and converted that into 8.82M in net income, yielding earnings per share of 0.22. EBITDA reached 7.36M, while operating income came in at 5.75M.
| Revenue | 56.22M |
| Gross Profit | 42.45M |
| Operating Income | 5.75M |
| Pretax Income | 8.86M |
| Net Income | 8.82M |
| EBITDA | 7.36M |
| EBIT | 5.75M |
| Earnings Per Share (EPS) | 0.22 |
BrainsWay Ltd. holds 59.77M in cash and equivalents against 6.71M in total debt, resulting in a net debt position of -58.64M. Total book value stands at -88.08M, with working capital of 55.07M providing operational flexibility.
| Cash & Cash Equivalents | 59.77M |
| Total Debt | 6.71M |
| Net Debt | -58.64M |
| Equity (Book Value) | -88.08M |
| Book Value Per Share | -2.28 |
| Working Capital | 55.07M |
BrainsWay Ltd. produced 14.18M in operating cash flow over the past twelve months. After subtracting -2.73M in capital expenditures, free cash flow totaled 11.45M - equivalent to 0.30 per share.
| Operating Cash Flow | 14.18M |
| Capital Expenditures | -2.73M |
| Free Cash Flow | 11.45M |
| FCF Per Share | 0.30 |
BrainsWay Ltd. operates with a gross margin of 75.51, reflecting its pricing power and cost economics. The operating margin of 10.23 and net profit margin of 15.68 provide insight into operational efficiency.
| Gross Margin | 75.51 |
| Operating Margin | 10.23 |
| Pretax Margin | 15.75 |
| Profit Margin | 15.68 |
| EBITDA Margin | 13.09 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.51 |
| FCF Yield | 3.57 |
BrainsWay Ltd. posts an Altman Z-Score of 6.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.83 |